Literature DB >> 2506841

Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities.

K Nagasawa1, Y Ishii, T Mayumi, Y Tada, A Ueda, Y Yamauchi, T Kusaba, Y Niho.   

Abstract

The pathogenesis of avascular necrosis of bone (ANB) was investigated in 111 patients with systemic lupus erythematosus (SLE) (24 with ANB, 87 without ANB); patients' ages, corticosteroid treatment, clinical and laboratory features associated with SLE, and haemostatic profiles were all taken into account. The mean ages of patients with and without ANB at the time of diagnosis of SLE was 24.1 and 31.2 years respectively. The mean maximal daily dose of prednisolone in the group with ANB was 50.8 mg, which was significantly higher than the dose (41.8 mg) in the group without ANB. Disease features of SLE, such as Raynaud's phenomenon, hyperlipidaemia, nephrotic syndrome, hypertension, and disease activity, were not found to be related to ANB. The percentage of patients who had lupus anticoagulant as well as a shorter activated partial thromboplastin time was greater in those with ANB than in those without. Multiple factors may be involved in the pathogenesis of ANB in SLE, and it is suggested that haemostatic abnormalities, which could be influenced by corticosteroids and young ages, play some part in the development of ANB.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506841      PMCID: PMC1003845          DOI: 10.1136/ard.48.8.672

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  25 in total

1.  ARTHRITIS ROUNDS. (4). ASEPTIC NECROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. REPORT OF A CASE INVOLVING SIX JOINTS.

Authors:  M RUDERMAN; D J MCCARTY
Journal:  Arthritis Rheum       Date:  1964-12

2.  ASEPTIC NECROSIS OF THE FEMORAL HEADS AFTER HIGH-DOSAGE CORTICOSTEROID THERAPY.

Authors:  R H FREIBERGER; G E SWANSON
Journal:  N Y State J Med       Date:  1965-03-15

3.  Hip problems associated with organ transplants.

Authors:  W R Murray
Journal:  Clin Orthop Relat Res       Date:  1973 Jan-Feb       Impact factor: 4.176

4.  Non-traumatic necrosis of the femoral head. I. Relation of altered hemostasis to etiology.

Authors:  W G Boettcher; M Bonfiglio; H H Hamilton; R F Sheets; K Smith
Journal:  J Bone Joint Surg Am       Date:  1970-03       Impact factor: 5.284

5.  Systemic lupus erythematosus (SLE) and aseptic bone necrosis. A discussion based on the presentation of one case treated with corticosteroids.

Authors:  I Goldie; G Tibblin; S Scheller
Journal:  Acta Med Scand       Date:  1967-07

6.  Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus.

Authors:  T M Zizic; C Marcoux; D S Hungerford; J V Dansereau; M B Stevens
Journal:  Am J Med       Date:  1985-11       Impact factor: 4.965

7.  Ischemic heart disease in systemic lupus erythematosus in the young patient: report of six cases.

Authors:  C J Homcy; R R Liberthson; J T Fallon; S Gross; L M Miller
Journal:  Am J Cardiol       Date:  1982-02-01       Impact factor: 2.778

8.  Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant.

Authors:  M L Boey; C B Colaco; A E Gharavi; K B Elkon; S Loizou; G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-08

9.  Avascular necrosis in SLE. An apparent predilection for young patients.

Authors:  F E Smith; D E Sweet; C M Brunner; J S Davis
Journal:  Ann Rheum Dis       Date:  1976-06       Impact factor: 19.103

10.  A nation-wide study of atherosclerosis in infants, children and young adults in Japan.

Authors:  K Tanaka; J Masuda; T Imamura; K Sueishi; T Nakashima; I Sakurai; T Shozawa; Y Hosoda; Y Yoshida; Y Nishiyama
Journal:  Atherosclerosis       Date:  1988-08       Impact factor: 5.162

View more
  20 in total

1.  Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?

Authors:  M Y Mok; V T Farewell; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  The antiphospholipid syndrome: a syndrome in evolution.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 3.  Subchondral insufficiency fracture of the femoral head in a patient with systemic lupus erythematosus.

Authors:  T Yamamoto; R Schneider; Y Iwamoto; P G Bullough
Journal:  Ann Rheum Dis       Date:  2006-06       Impact factor: 19.103

4.  The risk factors of avascular necrosis in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  Kao-Kao Zhu; Wang-Dong Xu; Hai-Feng Pan; Min Zhang; Jing Ni; Fu-Yang Ge; Dong-Qing Ye
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

5.  Symptomatic knee osteonecrosis in patients with systemic lupus erythematosus: a case-control study.

Authors:  Lidan Zhao; Xiuhua Wu; Honghua Wu; Jinmei Su; Wen Zhang; Yan Zhao; Xuan Zhang; Wenjie Zheng
Journal:  Rheumatol Int       Date:  2016-05-26       Impact factor: 2.631

Review 6.  Does vasculitis alone cause AVN? A review of literature.

Authors:  Rtika R Abraham; John O Meyerhoff
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

Review 7.  Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy.

Authors:  Waqar Haque; Huseyin Kadikoy; Omar Pacha; Joseph Maliakkal; Vu Hoang; Abdul Abdellatif
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

Review 8.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

Review 9.  Orthopedic involvement in antiphospholipid syndrome.

Authors:  Alexander Gorshtein; Yair Levy
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 10.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.